Could a sleep aid curb opioid relapse? new study tests suvorexant
NCT ID NCT04287062
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a sleep medication called suvorexant can improve sleep and reduce stress in people recovering from opioid addiction. About 138 participants on medications like methadone or buprenorphine were given either suvorexant or a placebo for 8 weeks. The goal was to see if better sleep and lower stress could help prevent relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Suvorexant (a sleep medication that blocks orexin, a brain chemical involved in wakefulness)
What this could lead to
If it works, this could point toward a way to improve sleep and lower stress in people recovering from opioid addiction, potentially reducing relapse risk.
What could go wrong
This is a Phase 2 trial with a moderate size (138 participants), so results may not apply to everyone. The drug may not improve sleep or stress significantly, and side effects like daytime drowsiness are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addiction Treatment Services at Johns Hopkins Bayview Medical Center
Baltimore, Maryland, 21224, United States
-
Ashley Addiction Treatment
Bel Air, Maryland, 21014, United States
-
Ashley Addiction Treatment
Elkton, Maryland, 21921, United States
-
Behavioral Pharmacology Research Unit at the Johns Hopkins Bayview Medical Center
Baltimore, Maryland, 21224, United States
-
Man Alive Inc., Lane Treatment Center
Baltimore, Maryland, 21218, United States